Saturday 17 October 2026
Export SMMT’s income statement to Excel — free account
Summit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00. In the quarter to June 2026, EPS grew 63.2% and free cash flow fell 112.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.63
0.74
−4.81%
Follow SMMT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
6.96 | 7.41 | 9.87 | 3.80 | |
Current Ratio |
6.96 | 7.41 | 9.87 | 3.80 | |
Net Debt/EBITDA |
3.13 | 3.16 | 3.12 | 1.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.65 | 0.65 | 0.47 | 0.40 | |
Capex/Depreciation |
(19.76) | (5.57) | (3.90) | (1.69) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.18) | (0.16) | (0.14) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | (0.16) | (0.14) | (0.13) | |
Cash per Share |
0.89 | 0.77 | 0.95 | 0.32 | |
Shareholders Equity per Share |
0.81 | 0.70 | 0.88 | 0.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.81 | 0.70 | 0.88 | 0.26 | |
Free Cash Flow |
(142.03) | (122.54) | (102.10) | (93.15) | |
Working Capital |
617.01 | 533.33 | 647.31 | 181.54 | |
Capital Expenditures |
(0.91) | (0.24) | (0.16) | (0.07) | |
Net Current Asset Value |
598.38 | 514.67 | 627.98 | 177.00 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
20.32 | 13.33 | 8.81 | 5.33 | |
Average Payables |
22.94 | 16.27 | 12.46 | 12.75 | |
Average Assets |
538.11 | 515.84 | 593.37 | 382.29 | |
Average Common Equity |
444.71 | 445.13 | 523.80 | 315.09 |
Columns are period end dates